The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited...

Full description

Bibliographic Details
Main Authors: Jeffrey M. Ryckman, Bradley N. Reames, Kelsey A. Klute, William A. Hall, Michael J. Baine, May Abdel-Wahab, Chi Lin
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Pancreatic cancer
Stereotactic body radiotherapy
Total neoadjuvant therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630821000392
Description
Summary:Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional nodes.
ISSN:2405-6308

Similar Items